Impact of donor vaccination on recipient response to early SARS-CoV-2 mRNA vaccination after allogeneic HSCT

Affiliations

• ¹ Haematology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération Hospitalo-Universitaire TRUE innovative therapy for immune disorders, Henri Mondor Hospital, Creteil 94000, France; INSERM U955, Paris Est Créteil University UPEC, Créteil, France.
• ² Haematology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération Hospitalo-Universitaire TRUE innovative therapy for immune disorders, Henri Mondor Hospital, Creteil 94000, France.
• ³ Virology Department, AP-HP, Henri Mondor Hospital, Créteil, France.
• ⁴ Etablissement Français du Sang, Ile de France, Créteil, France.
• ⁵ INSERM U955, Paris Est Créteil University UPEC, Créteil, France; Virology Department, AP-HP, Henri Mondor Hospital, Créteil, France.
• ⁶ Haematology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération Hospitalo-Universitaire TRUE innovative therapy for immune disorders, Henri Mondor Hospital, Creteil 94000, France; INSERM U955, Paris Est Créteil University UPEC, Créteil, France. Electronic address: sebastien.maury@aphp.fr.